Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887870 · ClinicalTrials.gov registry record · Phase 2
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT04887870 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT04887870, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Sitravatinib
- DRUG Enfortumab Vedotin-Ejfv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2025-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887870
The ClinicalTrials.gov registry entry for NCT04887870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04887870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04887870 about?
NCT04887870 is a clinical study titled "Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study". A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
What is the current status of trial NCT04887870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-06-29. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT04887870?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), Sitravatinib (DRUG), Enfortumab Vedotin-Ejfv (DRUG).
Who is sponsoring clinical trial NCT04887870?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.